CLIMB BIO, INC. Marketable Securities (Non-Current)
CLIMB BIO, INC. (CLYM) had Marketable Securities (Non-Current) of $56.10 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Long-Term Investments
us-gaap:MarketableSecuritiesNoncurrent · last filed 2026-08-06
- 2026-06-30: Marketable Securities, Noncurrent $56.10M.
- 2026-03-31: Marketable Securities, Noncurrent $36.74M.
- 2025-12-31: Marketable Securities, Noncurrent $59.57M.
- 2025-09-30: Marketable Securities, Noncurrent $88.93M.
| Period end | Marketable Securities, Noncurrent |
|---|---|
| 2026-06-30 | $56.10M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $36.74M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $59.57M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $88.93M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $102.70M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $99.78M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $61.61M 10-K · filed 2026-03-05 |
| 2024-09-30 | $24.58M 10-Q · filed 2024-11-12 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-25 |
| 2022-12-31 | $0.00 10-K · filed 2023-03-06 |
| 2022-09-30 | $6.96M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $11.70M 10-Q · filed 2022-08-15 |
| 2022-03-31 | $25.91M 10-Q · filed 2022-05-16 |
| 2021-12-31 | $24.92M 10-K · filed 2023-03-06 |
| 2021-09-30 | $23.62M 10-Q · filed 2021-11-08 |
| 2020-12-31 | $0.00 10-K · filed 2022-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |